These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12547502)

  • 1. Will we be able to 'spot' an effective HIV-1 vaccine?
    Yang OO
    Trends Immunol; 2003 Feb; 24(2):67-72. PubMed ID: 12547502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines from vaccine-induced HIV-1 specific cytotoxic T lymphocytes: effects on viral replication.
    Bollinger RC; Quinn TC; Liu AY; Stanhope PE; Hammond SA; Viveen R; Clements ML; Siliciano RF
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1067-77. PubMed ID: 7906131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the development of an HIV-1 vaccine.
    Letvin NL
    Science; 1998 Jun; 280(5371):1875-80. PubMed ID: 9632379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immunosuppressive infections and their treatment.
    Wodarz D; Nowak MA
    Philos Trans R Soc Lond B Biol Sci; 2000 Aug; 355(1400):1059-70. PubMed ID: 11186307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development.
    Wagner R; Deml L; Schirmbeck R; Reimann J; Wolf H
    Behring Inst Mitt; 1994 Dec; (95):23-34. PubMed ID: 7755506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV CTL escape: at what cost?
    Smith SM
    Retrovirology; 2004 May; 1():8. PubMed ID: 15169568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selection of HIV escape mutants by CTL and adaptation of HIV to HLA class I].
    Takiguchi M
    Uirusu; 2009 Dec; 59(2):145-53. PubMed ID: 20218323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic interplay between viral adaptation and immune recognition during HIV-1 infection.
    Motozono C; Mwimanzi P; Ueno T
    Protein Cell; 2010 Jun; 1(6):514-9. PubMed ID: 21204005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M cell DNA vaccination for CTL immunity to HIV.
    Wang X; Hone DM; Haddad A; Shata MT; Pascual DW
    J Immunol; 2003 Nov; 171(9):4717-25. PubMed ID: 14568947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.
    Becker Y
    Virus Genes; 1994 Jul; 8(3):249-70. PubMed ID: 7975271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.
    Koofhethile CK; Ndhlovu ZM; Thobakgale-Tshabalala C; Prado JG; Ismail N; Mncube Z; Mkhize L; van der Stok M; Yende N; Walker BD; Goulder PJR; Ndung'u T
    J Virol; 2016 Aug; 90(15):6818-6831. PubMed ID: 27194762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals.
    McElrath MJ; Corey L; Greenberg PD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S69-72. PubMed ID: 7865336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.
    Gorse GJ; Patel GB; Belshe RB;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1175-89. PubMed ID: 11522187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-specific cytotoxic T lymphocyte responses in patients infected with the human immunodeficiency virus, HIV-1.
    Rivière Y
    Cell Mol Biol (Noisy-le-grand); 1994; 40 Suppl 1():45-8. PubMed ID: 7950861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.
    Barouch DH; Kunstman J; Kuroda MJ; Schmitz JE; Santra S; Peyerl FW; Krivulka GR; Beaudry K; Lifton MA; Gorgone DA; Montefiori DC; Lewis MG; Wolinsky SM; Letvin NL
    Nature; 2002 Jan; 415(6869):335-9. PubMed ID: 11797012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV T-Cell Vaccines.
    Mothe B; Brander C
    Adv Exp Med Biol; 2018; 1075():31-51. PubMed ID: 30030788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization.
    Tobery TW; Siliciano RF
    J Exp Med; 1997 Mar; 185(5):909-20. PubMed ID: 9120397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.